FUDOSTEINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C6H13NO3S
Molecular Weight	179.237
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H](CSCCCO)C(O)=O

InChI

InChIKey=KINWYTAUPKOPCQ-YFKPBYRVSA-N

InChI=1S/C6H13NO3S/c7-5(6(9)10)4-11-3-1-2-8/h5,8H,1-4,7H2,(H,9,10)/t5-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549

Fudosteine is a derivative of cysteine developed and approved in Japan for the treatment of such diseases as bronchial asthma, chronic bronchitis, pulmonary emphysema, bronchiectasis, pulmonary tuberculosis, pneumoconiosis, atypical mycobacterial disease and diffuse panbronchiolitis. Fudosteine acts as a mucoactive agent, enabling mucin secretion. Although exact mechanism of action is unknown, it is supposed that fudosteine inhibits MUC5AC expression.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mucin-5AC 2 Target ID: P98088\|\|\|Q8N4M9 Gene ID: 4586.0 Gene Symbol: MUC5AC Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Bronchial asthma 50 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22349417	Palliative	Approved 8429	Unknown Approved Use Unknown
Chronic bronchitis 51 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22349417	Primary	Approved 8429	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 174 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22349417	Primary	Approved 8429	Unknown Approved Use Unknown
Bronchiectasis 3 Sources: http://www.ncbi.nlm.nih.gov/pubmed/22349417	Primary	Approved 8429	Unknown Approved Use Unknown
Pulmonary tuberculosis 17 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Primary	Approved 8429	Unknown Approved Use Unknown
Pneumoconiosis 1 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Primary	Approved 8429	Unknown Approved Use Unknown
Atypical mycobacterial disease 1 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Primary	Approved 8429	Unknown Approved Use Unknown
Diffuse panbronchiolitis 1 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18579549	Primary	Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effects of SS320A, a new cysteine derivative, on the change in the number of goblet cells induced by isoproterenol in rat tracheal epithelium.	1998 May	9639062
Inhibition of endotoxin- and antigen-induced airway inflammation by fudosteine, a mucoactive agent.	2005	15649854
Effect of fudosteine on mucin production.	2008 Nov	18579549

Patents

Sample Use Guides

In Vivo Use Guide

Fudosteine is an expectorant given orally in a dose of 400mg three times daily.

Route of Administration: Oral

In Vitro Use Guide

The human pulmonary mucoepidermoid carcinoma cell line NCI-H292 was cultured in RPMI 1640 media that contained 10% foetal bovine serum, penicillin (100 U*mL-1), streptomycin (100 mg*mL-1) and HEPES (25 mM) at 37C in a humidified 5% CO2 water-jacketed incubator. Fudosteine suppresses TNF-alpha-induced MUC5AC mucin secretion,albeit only at the concentration of 1 mM.

Name

Type

Language

FUDOSTEINE

Official Name

English

Fudosteine [WHO-DD]

Common Name

English

FUDOSTEINE [JAN]

Common Name

English

FUDOSTEINE [MART.]

Common Name

English

fudosteine [INN]

Common Name

English

(-)-3-((3-HYDROXYPROPYL)THIO)-L-ALANINE

Systematic Name

English

CLEANAL

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C74536